MedPath

New Generation Low Level Laser Effect in Myofacial Pain Syndrome

Not Applicable
Completed
Conditions
Myofascial Pain Syndrome
Registration Number
NCT06442553
Lead Sponsor
University of Gaziantep
Brief Summary

Low level laser treatments have been used to treat painful trigger points in myofascial pain syndrome (MPS), but the effectiveness of the appropriate laser type and parameters is still uncertain. The aim of this study was to compare the effectiveness of different types of low level laser treatment (LLLT) in reducing pain levels, changing oxygen saturation and bite force in patients with MPS.

Detailed Description

A total of 45 patients with MPS were randomly divided into three groups. First group received LLLT with GRR laser over massater muscle region. Patients in the second group were treated with Nd:YAG laser and the same protocol with Nd:YAG laser was performed in the placebo group using sham device. Pain was evaluated by visual analogue scale (VAS), change in oxygen concentration in the massater muscle was measured by functional near-infrared spectroscopy- fNIRS and bite force was measured with Flexiforce sensors before and after treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria

-patients with symptoms of temporomandibular disorders and diagnosed with MPS as a result of the clinical examination.

Exclusion Criteria
  • Patients with internal TMJ irregularities or degenerative joint changes,
  • patients with restricted mouth opening, deviation or deflection,
  • patients with systemic diseases,
  • pregnant women,
  • patients who had received MPS treatment within the previous year

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Primary Outcome Measures
NameTimeMethod
change from baseline in pain on the 10 point visual analogue scale (VAS) at week 3baseline and week 3

Patients were asked to rate the intensity of their pain on a scale from 0 to 10. They were told that a score of 0 meant no pain, a score of 10 meant severe pain and a score of 5 meant moderate pain

change from baseline in oxygen concentration in the massater muscle at week 3baseline and week 3

oxygen concentration in the massater muscle was measured by functional near-infrared spectroscopy- fNIRS (ARGES cerebro, Hemosoft Inc., Ankara, Turkey) before and after treatment for each patient.

change from baseline in bite force values at week 3baseline and week 3

bite force values were recorded by Flexiforce sensors before and after treatment for each patient.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

İrem Karagözoğlu

🇹🇷

Şehitkamil, Gazi̇antep, Turkey

İrem Karagözoğlu
🇹🇷Şehitkamil, Gazi̇antep, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.